Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.67
- Piotroski Score 6.00
- Grade Buy
- Symbol (AZN)
- Company AstraZeneca PLC
- Price $64.69
- Changes Percentage (1.32%)
- Change $0.84
- Day Low $63.38
- Day High $64.74
- Year High $87.68
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
- Last Earnings 07/25/2024
- Ex-Dividend for 5/16 Dividend 08/09/2024
- Dividend Payable 09/09/2024
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $85.00
- High Stock Price Target $89.00
- Low Stock Price Target $79.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.03
- Trailing P/E Ratio 39.42
- Forward P/E Ratio 39.42
- P/E Growth 39.42
- Net Income $5.96 B
Income Statement
Quarterly
Annual
Latest News of AZN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing
AstraZeneca has 25 investors holding a majority stake of 49%. Institutions own 72% and can influence market moves. Top shareholders include Capital Research and Management, BlackRock, and The Vanguard...
By Yahoo! Finance | 2 weeks ago -
AstraZeneca PLC (AZN): A Top Holding in George Soros's Portfolio
George Soros, a renowned investor and philanthropist, holds a net worth of $7.2 billion. AstraZeneca PLC (NASDAQ:AZN) is the top holding in his portfolio, with a 3.43% stake....
By Yahoo! Finance | 3 weeks ago -
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts?
AstraZeneca PLC (NASDAQ:AZN) is a cheap growth stock with promising earnings growth projections and a robust pipeline. Analysts recommend buying, expecting a 21% upside. Despite its potential, other A...
By Yahoo! Finance | 1 month ago
